Carcinoembryonic antigen: Difference between revisions
No edit summary |
|||
(6 intermediate revisions by 2 users not shown) | |||
Line 27: | Line 27: | ||
* Reference range: '''< 3 ug/l''' <ref>Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016</ref> | * Reference range: '''< 3 ug/l''' <ref>Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016</ref> | ||
'''Carcinoembryonic antigen''' (CEA) is a [[glycoprotein]] involved in [[cell adhesion]]. It is normally produced during fetal development, but the production of CEA stops before birth. Therefore, it is not usually present in the blood of healthy adults, although levels are raised in heavy smokers | '''Carcinoembryonic antigen''' (CEA) is a [[glycoprotein]] involved in [[cell adhesion]]. It is normally produced during fetal development, but the production of CEA stops before birth. Therefore, it is not usually present in the blood of healthy adults, although levels are raised in heavy smokers. | ||
==Pathophysiology== | |||
CEA and related [[genes]] make up the CEA family belonging to the [[immunoglobulin]] superfamily. In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. <ref>Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. ''Semin Cancer Biol'' 1999;9:67-81. PMID 10202129.</ref> | |||
==Historical perspective== | |||
CEA was first identified in 1965 by [[Phil Gold]] and [[Samuel O. Freedman]] in human [[colon cancer]] tissue extracts.<ref>Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. ''J Exp Med'' 1965;121:439. PMID 14270243.</ref> It was found that [[blood plasma|serum]] from individuals with colorectal, gastric, pancreatic, lung and breast [[carcinomas]] had higher levels of CEA than healthy individuals. | |||
==Diagnosis== | |||
CEA measurement is mainly used as a [[tumor marker]] to identify recurrences after surgical resection. Elevated CEA levels should return to normal after surgical resection, as elevation of CEA during follow up is an indicator of recurrence of tumour. | CEA measurement is mainly used as a [[tumor marker]] to identify recurrences after surgical resection. Elevated CEA levels should return to normal after surgical resection, as elevation of CEA during follow up is an indicator of recurrence of tumour. | ||
== Differential Diagnosis == | == Differential Diagnosis == | ||
Line 43: | Line 48: | ||
* [[Cervical Cancer]] | * [[Cervical Cancer]] | ||
* [[Cholangiocarcinoma]] | * [[Cholangiocarcinoma]] | ||
* [[Cirrhosis]] | |||
* [[Colorectal tumor]]s | * [[Colorectal tumor]]s | ||
* [[Emphysema]] | * [[Emphysema]] | ||
Line 54: | Line 60: | ||
* [[Pancreatic Cancer]] | * [[Pancreatic Cancer]] | ||
* [[Pancreatitis]] | * [[Pancreatitis]] | ||
* Recurrence of cancer | |||
* [[Smoking]] | * [[Smoking]] | ||
* [[Stomach cancer]] | * [[Stomach cancer]] | ||
* [[Thyroid cancer]] | * [[Thyroid cancer]] | ||
* Tumor recurrence | |||
* [[Ulcerative colitis]] | * [[Ulcerative colitis]] | ||
Line 65: | Line 73: | ||
{{Cell adhesion molecules}} | {{Cell adhesion molecules}} | ||
{{Tumor markers}} | {{Tumor markers}} | ||
[[Category:Tumor markers]] | [[Category:Tumor markers]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Laboratory Test]] | [[Category:Laboratory Test]] |
Latest revision as of 17:07, 17 August 2015
carcinoembryonic antigen-related cell adhesion molecule 5 | |
---|---|
Identifiers | |
Symbol | CEACAM5 |
Alt. symbols | CEA |
Entrez | 1048 |
HUGO | 1817 |
OMIM | 114890 |
RefSeq | NM_004363 |
UniProt | P06731 |
Other data | |
Locus | Chr. 19 q13.1-13.2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
- Carcinoembryonic antigen (CEA) is a protein-polysaccharide complex
- Located in colon carcinomas, fetal intestine, liver and pancreas
- Reference range: < 3 ug/l [1]
Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. It is normally produced during fetal development, but the production of CEA stops before birth. Therefore, it is not usually present in the blood of healthy adults, although levels are raised in heavy smokers.
Pathophysiology
CEA and related genes make up the CEA family belonging to the immunoglobulin superfamily. In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. [2]
Historical perspective
CEA was first identified in 1965 by Phil Gold and Samuel O. Freedman in human colon cancer tissue extracts.[3] It was found that serum from individuals with colorectal, gastric, pancreatic, lung and breast carcinomas had higher levels of CEA than healthy individuals.
Diagnosis
CEA measurement is mainly used as a tumor marker to identify recurrences after surgical resection. Elevated CEA levels should return to normal after surgical resection, as elevation of CEA during follow up is an indicator of recurrence of tumour.
Differential Diagnosis
In alphabetical order. [4] [5]
Increased
- Alcoholic Cirrhosis
- Breast Cancer
- Bronchial carcinoma
- Cervical Cancer
- Cholangiocarcinoma
- Cirrhosis
- Colorectal tumors
- Emphysema
- Gastric carcinoma
- Inflammatory Bowel Disease
- Inflammatory liver diseases
- Medullar thyroid carcinoma
- Mesothelioma
- Neuroendocrine tumors
- Ovarian Cancer
- Pancreatic Cancer
- Pancreatitis
- Recurrence of cancer
- Smoking
- Stomach cancer
- Thyroid cancer
- Tumor recurrence
- Ulcerative colitis
References
- ↑ Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
- ↑ Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81. PMID 10202129.
- ↑ Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439. PMID 14270243.
- ↑ Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
- ↑ Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X